Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
From the article
You might also wanna read
Lenacapavir and the shift to NRTI-free, long-acting HIV treatment: implications for HBV patients
The article discusses the evolving HIV treatment landscape, focusing on the shift toward NRTI-free dual regimens and long-acting injectable
FDA Approves First 100% Effective HIV Prevention Drug with Global Impact
The article discusses the milestone approval of the first HIV prevention drug, lenacapavir (brand name Yeztugo), which offers 100% protectio
newatlas.com·11mo ago
Proposed NIH Budget Cuts Threaten HIV Breakthroughs Like Lenacapavir, Article Argues
The article argues that proposed Trump administration cuts to NIH funding—specifically a ~40% reduction to $27.9 billion for FY2026—would se
thinkglobalhealth.org·20d ago
Correspondence: Nirmatrelvir–ritonavir suppresses viral load but may attenuate spike antibody response
This correspondence article discusses findings from the PANORAMIC trial published in The Lancet Microbe, showing that nirmatrelvir–ritonavir
Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention
This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisatio
PARTNERS trial begins enrolling patients in DRC to test treatments for Bundibugyo virus disease
The PARTNERS clinical trial has begun enrolling patients in the Democratic Republic of the Congo to evaluate potential treatments for Bundib
who.int·6d agoPARTNERS trial begins enrolling patients in DRC to test treatments for Bundibugyo virus disease
The PARTNERS clinical trial has begun enrolling patients in the Democratic Republic of the Congo to evaluate potential treatments for Bundib
who.int·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.